生物活性：Dexpramipexole-d3 (dihydrochloride) is the deuterium labeled Dexpramipexole. Dexpramipexole((R)-Pramipexole), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist[1][2].
IC50 & Target：D3 Receptor
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Dexpramipexole-d3 dihydrochloride 相关抗体:
DRD2 Antibody
Dopamine Receptor D3 Antibody (YA1742)
DOPA Decarboxylase Antibody (YA2428)
Dopamine Receptor D1 Antibody (YA3270)
Torsin 1A Antibody (YA2935)
PITX3 Antibody (YA2974)
HMBS Antibody (YA3061)
分子量：287.27
Formula：C10H16D3Cl2N3S
CAS 号：1432230-09-5
非标记 CAS：104632-27-1
中文名称：普拉克索杂质E-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (526 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler
 [Content Brief]
[3]. Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11.
 [Content Brief]
[4]. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6.
 [Content Brief]
[5]. Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51(8):1177-85.
 [Content Brief]
[6]. Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20.
 [Content Brief]